6533b826fe1ef96bd128531f
RESEARCH PRODUCT
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.
Kieninger Dorothee MKueper KathrinSteul KatrinJuergens ChristineAhlers NorbertBaker SherrylJansen Kathrin UDevlin CarmelGruber William CEmini Emilio AScott Daniel AZimmer Johannessubject
SerotypeMaleHeptavalent Pneumococcal Conjugate Vaccinemedicine.disease_causecomplex mixturesPneumococcal conjugate vaccinePneumococcal InfectionsPneumococcal Vaccinesstomatognathic systemDouble-Blind MethodGermanyStreptococcus pneumoniaemedicineHeptavalent Pneumococcal Conjugate VaccineHumansImmunization ScheduleVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthInfantmedicine.diseaseAntibodies BacterialVaccinationPneumococcal infectionsInfectious DiseasesImmunizationImmunoglobulin GImmunologyMolecular MedicineFemalebusinessmedicine.drugdescription
13-valent pneumococcal conjugate vaccine (PCV13) was compared to PCV7 in infants administered 4 doses. For the 7 common serotypes, PCV13- and PCV7-elicited responses showed comparable percent responders achieving 0.35mug/mL IgG threshold (exception 6B, 77.5% versus 87.1%, respectively) and OPA titers of 1:8; IgGs were lower than PCV7 but functional responses were generally comparable. For the 6 additional serotypes, PCV13-elicited IgG and functional OPA responses were notably greater than PCV7. The toddler dose boosted immune responses. Vaccines were comparable with regard to safety. PCV13 should be as effective as PCV7 in preventing pneumococcal disease caused by the common serotypes and may provide protection against the additional serotypes.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2010-06-01 | Vaccine |